Kezdőlap・Részvénylista・Krystal Biotech Inc

Krystal Biotech Inc

Lezárt

SzektorEgészségügy

331.08 -0.8

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

329.21

Maximum

336.59

Fő mutatók
By Trading Economics
Bevétel	-1.2M 55M
Értékesítés	2.9M 119M
P/E Szektor átlag	42.019 57.371
Egy részvényre jutó nyereség	1.79
Profit margin	45.938
Munkavállalók	295
EBITDA	2.9M 66M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+19.94% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 2.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-434M 9.9B
Előző nyitás	331.88
Előző zárás	331.08

Hangulat hírek alapján

By Acuity

22%

78%

66 / 340 Rangsor szerint Healthcare

Krystal Biotech Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 14. 19:46 UTC

News

RBC Capital initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, boosting shares higher since Thursday's close.

2026. aug. 13. 19:46 UTC

Correlated Moves

Krystal Biotech Inc shares are lower, reflecting a broader decline in the biotechnology sector and trading below their 20-day moving average.

2026. aug. 12. 20:52 UTC

Krystal Biotech Inc shares declined during after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

2026. aug. 11. 21:01 UTC

Krystal Biotech Inc. shares rose in after-market trading, reaching a high of 1.23% above Tuesday's close, despite remaining below its 20-day moving average.

2026. aug. 7. 19:26 UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

2026. aug. 6. 19:26 UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

2026. aug. 5. 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

2026. aug. 4. 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

2026. aug. 3. 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

2026. júl. 31. 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

2026. júl. 30. 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

2026. júl. 29. 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

2026. júl. 28. 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

2026. júl. 27. 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

2026. júl. 24. 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

2026. júl. 23. 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

2026. júl. 22. 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

2026. júl. 21. 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

2026. júl. 20. 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Társak összehasonlítása

Árváltozás

Krystal Biotech Inc Előrejelzés

Célár

By TipRanks

19.94% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 402.67 USD 19.94%

Magas 474 USD

Alacsony 361 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Krystal Biotech Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

8 ratings

Vétel

Tartás

Eladás

8 Wall Street elemző célárain alapulva a(z)Krystal Biotech Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

66 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.